يحاول ذهب - حر

Digital Innovations in Diabetes Care

BioSpectrum Asia Nov 2024

|

BioSpectrum Asia

Diabetes affects 537 million people globally and is a major contributor to the non-communicable disease NCD) epidemic. Technological tools such as continuous glucose monitors CGMs) and mobile apps are redefining diabetes management. On this World Diabetes Day November 14, 2024), we explore how digital health is transforming diabetes care and the challenges associated with its integration into healthcare systems.

- Ayesha Siddiqui

Digital Innovations in Diabetes Care

Diabetes affects 1 in 11 adults, or about 90 million people, in South-East Asia, with this number projected to rise to 113 million by 2030 and 151 million by 2045. Alarmingly, over half of these individuals remain undiagnosed. In 2021, diabetes caused 747,000 deaths in the region, and the economic burden of managing the disease reached $10 billion, as per the 2021 IDF Diabetes Atlas.

Technological advancements have proven to be a boon for diabetes care, offering various tools to help manage the condition effectively. One of the critical aspects of diabetes management is maintaining optimal glucose levels at all times. Digital health tools, such as continuous glucose monitors (CGMs), connected insulin pens, portable A1C monitors, and mobile apps, are transforming the way patients manage their condition outside of hospitals. Mobile apps enable healthcare providers to create personalised treatment plans based on real-time data.

Another innovation is the automated insulin delivery (AID) system, which integrates CGMs and insulin pumps to adjust insulin delivery continuously based on glucose data. Portable A1C monitors allow patients to measure their A1C levels at home, an essential marker for long-term diabetes management.

“Previously, patients had limited information about their condition, which led to anxiety and a lack of motivation for managing it. Now, with tools like CGMs, personal A1C monitors, and mobile apps, patients can check their levels anytime, anywhere, and easily access professional support through mobile platforms. This not only reduces uncertainty but also empowers them to receive more frequent feedback, stay motivated, and proactively manage their health. Ultimately, this leads to better health outcomes by making diabetes management more accessible and proactive,” said Yeaseul Park, Co-Founder and Co-President Orange Biomed, USA.

المزيد من القصص من BioSpectrum Asia

BioSpectrum Asia

Repligen introduces next-generation chromatography resins

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India

Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh

\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.

time to read

1 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cartherics names Dr lan Nisbet as CEO

Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Neurophet ropes in Josh Cohen as Head of Americas Business

South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

India's Final Mile to TB Elimination

As the target year 2025 draws to a close, the Government of India has intensified and consolidated nationwide efforts to eliminate tuberculosis (TB) through the TB-Mukt Bharat Abhiyaan, implemented under the National Tuberculosis Elimination Programme (NTEP). India's decision to advance the TB elimination timeline ahead of global targets has driven sustained reforms across detection, treatment, prevention, nutrition support, and community engagement.

time to read

2 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Korea builds AI-engineered nasal spray antiviral platform

A research team at Korea Advanced Institute of Science and Technology has successfully developed a nasal (intranasal) antiviral platform using artificial intelligence (AI) technology to overcome the existing limitations of interferonlambda treatments, namely, being weak against heat and disappearing quickly from the nasal mucosa.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

"Industry needs to evolve and invest in ADC payloads with more differentiated mechanisms of action

Antibody drug conjugates (ADCs) are becoming highly valuable in the market, with currently 15 approved ADCs targeting 16 different indications for haematological and solid tumour malignancies. With key components of ADCs, such as mAbs, linkers, payloads, and conjugation technologies, undergoing rapid advancements, a solid foundation has been laid for future research and development in this field, particularly in North America which is the largest market shareholder for ADCs. US recently wrapped up the world's largest & definitive Antibody-Drug Conjugate event, World ADC, held in November 2025, highlighting the development of novel ADCs through key market players, and a surge in patent application filing for ADCs. Dr Allan Jordan, Vice President of Oncology Drug Discovery at Sygnature Discovery, UK spoke in detail with BioSpectrum Asia about the future outlook of ADCs.

time to read

4 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cytiva and Fida Biosystems collaborate to improve molecular insight for faster drug discovery

Cytiva, a Danaher company and leader in the life sciences industry, and Fida Biosystems, a Danish company specialising in molecular analysis, have joined forces to expand analytical capabilities for protein research.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Excellence Awards Highlight Strength and Future of India's Biotechnology Sector

Former Secretary, Department of Biotechnology (DBT), Government of India, Dr Renu Swarup, underscored the importance of recognising excellence across the biotechnology ecosystem while chairing the jury at the BioSpectrum Excellence Awards.

time to read

1 min

BioSpectrum Asia Jan 2026

Listen

Translate

Share

-
+

Change font size